目的检测疫苗生产用人二倍体细胞2BS和MRC-5是否存在外源因子猪圆环病毒1型(porcine circovirus type 1,PCVl)和猪圆环病毒2型(PCV2)污染。方法对已建立的PCR方法进行灵敏度验证后,检测人二倍体细胞2BS和MRC-5中PCV1和PCV2污染情况。结...目的检测疫苗生产用人二倍体细胞2BS和MRC-5是否存在外源因子猪圆环病毒1型(porcine circovirus type 1,PCVl)和猪圆环病毒2型(PCV2)污染。方法对已建立的PCR方法进行灵敏度验证后,检测人二倍体细胞2BS和MRC-5中PCV1和PCV2污染情况。结果两种细胞上清中最低均可检出1 pg的PCV1和PCV2 DNA,灵敏度较高;两种细胞中PCV检测结果均为阴性。结论在生产用人二倍体细胞2BS和MRC5中,均未检出PCV1和PCV2污染。展开更多
<div style="text-align:justify;"> <span style="font-family:Verdana;">Enteroviruses are responsible for emerging diseases which cause diverse symptoms and may result in neurological comp...<div style="text-align:justify;"> <span style="font-family:Verdana;">Enteroviruses are responsible for emerging diseases which cause diverse symptoms and may result in neurological complications. An antiviral with multiple mechanisms of action can help prevent enterovirus mediated disease despite differences in the pathogenesis between enteroviruses, including the recently identified enterovirus 69 (EV-69) for which pathogenesis is not well understood. This study investigated the efficacy of epigallocatechin-3-gallate stearate (EGCG-S), a modified form of the antioxidant green tea catechin epigallocatechin-3-gallate (EGCG), in inhibiting EV-69 infection of lung fibroblast cells </span><i><span style="font-family:Verdana;">in vitro</span></i><span style="font-family:Verdana;">. Treatment with EGCG-S resulted in moderate protection from EV-69 mediated cytotoxicity as demonstrated by increased metabolic activity as well as maintenance of cell morphology and mitochondrial function. These effects were correlated with reduced hydrogen peroxide production in infected cells following EGCG-S treatment with concentrations less than 100 μM, suggesting a role for inhibition of EV-69 mediated oxidative stress. This study provides insight into characteristics of EV-69 infection as well as the efficacy of EGCG-S mediated inhibition of EV-69 infection.</span> </div>展开更多
文摘<div style="text-align:justify;"> <span style="font-family:Verdana;">Enteroviruses are responsible for emerging diseases which cause diverse symptoms and may result in neurological complications. An antiviral with multiple mechanisms of action can help prevent enterovirus mediated disease despite differences in the pathogenesis between enteroviruses, including the recently identified enterovirus 69 (EV-69) for which pathogenesis is not well understood. This study investigated the efficacy of epigallocatechin-3-gallate stearate (EGCG-S), a modified form of the antioxidant green tea catechin epigallocatechin-3-gallate (EGCG), in inhibiting EV-69 infection of lung fibroblast cells </span><i><span style="font-family:Verdana;">in vitro</span></i><span style="font-family:Verdana;">. Treatment with EGCG-S resulted in moderate protection from EV-69 mediated cytotoxicity as demonstrated by increased metabolic activity as well as maintenance of cell morphology and mitochondrial function. These effects were correlated with reduced hydrogen peroxide production in infected cells following EGCG-S treatment with concentrations less than 100 μM, suggesting a role for inhibition of EV-69 mediated oxidative stress. This study provides insight into characteristics of EV-69 infection as well as the efficacy of EGCG-S mediated inhibition of EV-69 infection.</span> </div>
